1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H1 2020, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.
Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 1, 1, 1, 2, 11, 1 and 1 respectively.
Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Macular Edema - Overview
- Macular Edema - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Macular Edema - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Macular Edema - Companies Involved in Therapeutics Development
- Anew Oncology Inc
- AsclepiX Therapeutics Inc
- Celon Pharma SA
- Clearside BioMedical Inc
- Coherus BioSciences Inc
- F. Hoffmann-La Roche Ltd
- Formycon AG
- Lupin Ltd
- Luye Pharma Group Ltd
- Mabion SA
- OMEICOS Therapeutics GmbH
- PharmAbcine Inc
- Polus Inc
- Profarma
- Sustained Nano Systems LLC
- Taiwan Liposome Co Ltd
- Targeted Therapy Technologies LLC
- Tarsius Pharma Ltd
- Xbrane Biopharma AB
- Macular Edema - Drug Profiles
- ACX-107 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- bevacizumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Macular Edema - Dormant Projects
- Macular Edema - Discontinued Products
- Macular Edema - Product Development Milestones
- Featured News & Press Releases
- Apr 28, 2020: Clearside Biomedical revises NDA resubmission timeline and XIPERE commercial partnership with Bausch Health
- Jan 28, 2020: Bausch Health and Clearside Biomedical announce publication of PIVOTAL phase 3 data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology
- Aug 22, 2019: Clearside Biomedical provides new drug application update for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension)
- Jul 31, 2019: Clearside Biomedical announces multiple oral presentations delivered at the American Society of Retinal Specialists (ASRS) Annual Meeting
- May 01, 2019: Clearside Biomedical presents on Triamcinolone at the American Uveitis Society Spring Meeting 2019
- Apr 18, 2019: Clearside Biomedical announces presentations on its Suprachoroidal Space injection platform with Triamcinolone Acetonide at upcoming medical meetings
- Feb 20, 2019: Clearside Biomedical receives notification of FDA acceptance of NDA filing for XIPERE (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection with PDUFA Date Set for October 19, 2019
- Jan 20, 2019: Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE Exhibits Durability Following Second Dose
- Dec 19, 2018: Clearside Biomedical submits New Drug Application for XIPERE for the treatment of Macular Edema associated with Uveitis
- Oct 29, 2018: Presentation of additional analyses of Clearsides PEACHTREE clinical trial data further supports potential of XIPERE in treating uveitic macular edema
- Oct 22, 2018: CLEARSIDE, XIPERE and PEACHTREE to be front and center at AAO 2018
- Sep 18, 2018: Positive PEACHTREE Data to be Highlighted at EURETINA 2018
- Sep 13, 2018: Data from Clearside Biomedical’s pivotal phase 3 PEACHTREE clinical trial in macular edema associated with non-infectious uveitis to be presented at the Retina Society 51st Annual Scientific Meeting
- Sep 12, 2018: Single suprachoroidal steroid injection boosts visual acuity in patients with macular edema
- Jul 16, 2018: Clearside Biomedical to Present Data from its Pivotal Phase 3 (PEACHTREE) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact
- Disclaimer
List of Tables
- Number of Products under Development for Macular Edema, H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Macular Edema - Pipeline by Anew Oncology Inc, H1 2020
- Macular Edema - Pipeline by AsclepiX Therapeutics Inc, H1 2020
- Macular Edema - Pipeline by Celon Pharma SA, H1 2020
- Macular Edema - Pipeline by Clearside BioMedical Inc, H1 2020
- Macular Edema - Pipeline by Coherus BioSciences Inc, H1 2020
- Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
- Macular Edema - Pipeline by Formycon AG, H1 2020
- Macular Edema - Pipeline by Lupin Ltd, H1 2020
- Macular Edema - Pipeline by Luye Pharma Group Ltd, H1 2020
- Macular Edema - Pipeline by Mabion SA, H1 2020
- Macular Edema - Pipeline by OMEICOS Therapeutics GmbH, H1 2020
- Macular Edema - Pipeline by PharmAbcine Inc, H1 2020
- Macular Edema - Pipeline by Polus Inc, H1 2020
- Macular Edema - Pipeline by Profarma, H1 2020
- Macular Edema - Pipeline by Sustained Nano Systems LLC, H1 2020
- Macular Edema - Pipeline by Taiwan Liposome Co Ltd, H1 2020
- Macular Edema - Pipeline by Targeted Therapy Technologies LLC, H1 2020
- Macular Edema - Pipeline by Tarsius Pharma Ltd, H1 2020
- Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2020
- Macular Edema - Dormant Projects, H1 2020
- Macular Edema - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Macular Edema, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Anew Oncology Inc
- AsclepiX Therapeutics Inc
- Celon Pharma SA
- Clearside BioMedical Inc
- Coherus BioSciences Inc
- F. Hoffmann-La Roche Ltd
- Formycon AG
- Lupin Ltd
- Luye Pharma Group Ltd
- Mabion SA
- OMEICOS Therapeutics GmbH
- PharmAbcine Inc
- Polus Inc
- Profarma
- Sustained Nano Systems LLC
- Taiwan Liposome Co Ltd
- Targeted Therapy Technologies LLC
- Tarsius Pharma Ltd
- Xbrane Biopharma AB
